eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

The impact of CRTH2 antagonist OC 000459 on pulmonary function of asthma patients: a meta-analysis of randomized controlled trials

Meng Tang
1
,
Yan Zhang
2
,
Ying Chen
1

1.
Department of Respiration, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China
2.
Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China
Adv Dermatol Allergol 2021; XXXVIII (4): 566–571
Online publish date: 2020/01/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The chemoattractant receptor expressed on T-helper (Th) type 2 cells (CRTH2) antagonist OC 000459 showed the potential in improving pulmonary function of asthma patients. Aim: We conducted a systematic review and meta-analysis to explore the impact of CRTH2 antagonist OC 000459 on pulmonary function for asthma.

Material and methods
PubMed, Embase, Web of science, EBSCO, and Cochrane library databases were systematically searched. This meta-analysis included randomized controlled trials (RCTs) assessing the effect of CRTH2 anta­gonist OC 000459 on pulmonary function for asthma. Two investigators independently searched articles, extracted data, and assessed the quality of included studies.

Results
Four RCTs were included in the meta-analysis. Overall, compared with the control intervention for asthma patients, CRTH2 antagonist OC 000459 could significantly improve FEV1 (SMD = 0.22; 95% CI: 0.02–0.42; p = 0.03), peak expiratory flow (SMD = 0.22; 95% CI: 0.01–0.42; p = 0.04) and reduce the respiratory tract infection (RR = 0.47; 95% CI: 0.26–0.85; p = 0.01), but revealed no remarkable effect on predicted FEV1 (SMD = 0.14; 95% CI: –0.18 to 0.45; p = 0.39), or treatment-related adverse events (RR = 0.84; 95% CI: 0.52–1.36; p = 0.48).

Conclusions
CRTH2 antagonist OC 000459 might be effective and safe to improve pulmonary function in asthma patients.

keywords:

CRTH2 antagonist, OC 000459, pulmonary function, asthma, randomized controlled trial

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe